| Aurinia Pharmaceuticals Inc. |
Director |
Common Shares |
24,807 |
$209,123 |
$8.43 |
21 Nov 2024 |
Direct |
| Cortexyme, Inc. |
Chief Medical Officer |
Common Stock |
194,690 |
$183,009 |
$0.9400 |
19 May 2022 |
Direct |
| SANGAMO THERAPEUTICS, INC |
Director |
Common Stock |
102,100 |
$46,966 |
$0.4600 |
12 Jun 2025 |
Direct |
| Emergent BioSolutions Inc. |
EVP, Chief Medical Officer |
Common Stock |
11,888 |
$21,636 |
$1.82 |
07 May 2021 |
Direct |
| Skye Bioscience, Inc. |
Director |
Stock Option (Right to Buy) |
35,000 |
$1,190 |
$0.0170 |
24 Feb 2025 |
Direct |
| Quince Therapeutics, Inc. |
Chief Medical Officer |
Employee Stock Option (right to buy) |
225,000 |
|
|
01 Feb 2023 |
Direct |
| Context Therapeutics Inc. |
Director |
Stock Option (right to buy) |
123,500 |
|
|
12 Jun 2025 |
Direct |
| SANGAMO THERAPEUTICS, INC |
Director |
Stock Option (Right to Buy) |
50,000 |
|
|
12 Jun 2025 |
Direct |
| Skye Bioscience, Inc. |
Director |
Director Stock Option (Right to Buy) |
40,000 |
|
|
02 Jul 2024 |
Direct |
| Talaris Therapeutics, Inc. |
Director |
Stock Option (Right to Buy) |
20,500 |
|
|
13 Jun 2023 |
Direct |
| Aurinia Pharmaceuticals Inc. |
Director |
Director Stock Option (right to buy) |
18,641 |
|
|
21 Nov 2024 |
Direct |
| ACCELERON PHARMA INC |
Director |
Common Stock |
0 |
|
$175.00 |
19 Nov 2021 |
Direct |
| ACCELERON PHARMA INC |
Director |
Option to Purchase Common Stock |
0 |
|
|
19 Nov 2021 |
Direct |
| ANTARES PHARMA, INC. |
Director |
Common Stock |
0 |
|
$5.60 |
24 May 2022 |
Direct |
| ANTARES PHARMA, INC. |
Director |
Stock Option (right to buy) |
0 |
|
|
24 May 2022 |
Direct |
| Aurinia Pharmaceuticals Inc. |
Director |
Restricted Stock Units |
0 |
|
|
08 Nov 2024 |
Direct |